Professor David Price
Chair of Primary Care Respiratory Med
- About
-
- Email Address
- d.price@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437237
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Publications
-
Page 3 of 17 Results 101 to 150 of 833
S117 Poor adherence in exacerbating COPD patients: magnitude and related factors at baseline in the MAGNIFY pragmatic trial
Thorax, vol. 77, no. Suppl. 1, A72Contributions to Journals: AbstractsCharacterization of patients in the International Severe Asthma Registry with high steroid exposure who did or did not initiate biologic therapy
Journal of Asthma and Allergy, vol. 15, no. 15, pp. 1491—1510Contributions to Journals: ArticlesClinical outcomes in patients with severe asthma who had or had not initiated biologic therapy: results from the CLEAR study
CHEST 2022, pp. A28-A32Contributions to Journals: AbstractsClinical Review: The suggested management pathway for urticaria in primary care
Clinical and Translational Allergy, vol. 12, no. 10, e12195Contributions to Journals: ArticlesClinical outcomes and emergency healthcare utilization in patients with severe asthma who continued, switched or stopped biologic therapy: results from the CLEAR study
CHEST Annual Meeting, pp. A23-A27Contributions to Journals: AbstractsShort-acting β2-agonist prescription patterns for asthma management in the SABINA III primary care cohort
npj Primary Care Respiratory Medicine, vol. 32, 37Contributions to Journals: ArticlesSuboptimal peak inspiratory flow and critical inhalation errors are associated with higher COPD-related healthcare costs
International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 2401-2415Contributions to Journals: ArticlesOral corticosteroids in asthma and beyond: moving forward
European Respiratory Journal, vol. 60, no. 3, 2200776Contributions to Journals: EditorialsPatients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy
International journal of chronic obstructive pulmonary disease , vol. 2022, no. 17, pp. 2187—2200Contributions to Journals: ArticlesPersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
NexusContributions to Conferences: AbstractsOral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma
European Respiratory Society (ERS) International Congress., 4420Contributions to Journals: AbstractsOver-the-counter (OTC) short-acting β2-agonist (SABA) purchase and asthma outcomes in SABINA III
European Respiratory Society (ERS) International Congress.Contributions to Journals: AbstractsPatient-reported barriers to accepting a technological adherence package in the MAGNIFY trial
European Respiratory Society (ERS) International Congress., 3402Contributions to Journals: AbstractsSociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study
European Respiratory Society (ERS) International Congress., 3397Contributions to Journals: AbstractsMortality Analyses on Systemic Corticosteroid Use: a Long-term Observational Study
BTS Winter Meeting 2021, pp. A7-A8Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1136/thorax-2021-BTSabstracts.11
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstream/2164/23330/1/Xu_etal_BTS2021_Mortality_Analyses_On_AAM.pdf
- [ONLINE] https://www.brit-thoracic.org.uk/document-library/winter-meetings/winter-meeting-2021/winter-meeting-2021-abstract-programme/
Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
Eastern Pulmonary Conference 2022Contributions to Conferences: AbstractsA pragmatic primary practice approach to using specific IgE in allergy testing in asthma diagnosis, management, and referral
Journal of Asthma and Allergy, vol. 2022, no. 15, pp. 1069—1080Contributions to Journals: ArticlesPersistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study
World Allergy Congress 2022Contributions to Conferences: AbstractsCorrespondence to Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2LEN consensus
Allergy, vol. 77, no. 8, pp. 2571-2573Contributions to Journals: Letters- [ONLINE] DOI: https://doi.org/10.1111/all.15281
- [ONLINE] View publication in Scopus
Dupilumab Treatment Leads to Sustained Reductions in Oral Corticosteroid Use in Patients With Oral Corticosteroid–Dependent Severe Asthma
CHEST 2022Contributions to Conferences: AbstractsCOPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry
Annals of Family Medicine, vol. 20, no. 4, pp. 319-327Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1370/afm.2829
Oral corticosteroid (OCS) risk predictor for Type II Diabetes in asthma
European Respiratory Society (ERS) International Congress.Contributions to Conferences: AbstractsA Response to: Letter to the Editor Regarding “Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab”
Advances in Therapy, vol. 39, no. 8, pp. 3862-3865Contributions to Journals: LettersPersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
17th Annual Deutscher Allergiekongress (DAK) 2022Contributions to Conferences: AbstractsCharacterisation of the Australian adult population living with asthma: Severe exacerbation frequency, long-term OCS use and adverse effects.
Pragmatic and Observational Research, vol. 2022, pp. 43-58Contributions to Journals: ArticlesHealthcare resource utilisation associated with intermittent oral corticosteroid use in asthma
EAACI HYBRID CONGRESS 2022Contributions to Conferences: AbstractsBiologics in severe asthma: the role of real-world evidence from registries
European Respiratory Review, vol. 31, no. 164, 210278Contributions to Journals: ArticlesPersistent OCS reduction regardless of starting OCS dose in patients with severe, OCS-dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study
15º Congreso ALAT 2022Contributions to Conferences: AbstractsLet’s improve COPD prognosis: a practical tool for primary care providers to identify the frequency and follow-up of COPD lung attacks
Dutch Lung Congress 2022Contributions to Conferences: AbstractsReply to: Cause or consequence?
European Respiratory Journal, vol. 59, no. 6, 2200103Contributions to Journals: Comments and DebatesReducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial
The Lancet. Respiratory medicine, vol. 10, no. 6, pp. 584-592Contributions to Journals: ArticlesQuality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective
Advances in Therapy, vol. 39, pp. 2302–2322Contributions to Journals: ArticlesTreatment guided by fractional exhaled nitric oxide in addition to standard care in 6- to 15-year-olds with asthma: the RAACENO RCT
Efficacy and Mechanism Evaluation, vol. 9, no. 4, pp. 1-153Contributions to Journals: ArticlesFactors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers
npj Primary Care Respiratory Medicine, vol. 32, no. 1, 18Contributions to Journals: ArticlesSustained Improvement in Clinical Efficacy, Asthma Control, and Quality of Life in Patients With Severe, Oral Corticosteroid (OCS)-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
EAACI HYBRID CONGRESS 2022Contributions to Conferences: AbstractsPersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
2022 AANP National ConferenceContributions to Conferences: PostersEvaluation of critical inhalation technique errors in patients with COPD on Dry Powder Inhaler maintenance therapy based on their association with health status: findings from the PIFotal study.
IPCRG 2022Contributions to Conferences: Abstracts- [ONLINE] https://www.ipcrg.org/13436
Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study
European Respiratory Journal, vol. 59, no. 5Contributions to Journals: ArticlesPersistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study
The 35th annual
Eastern Allergy ConferenceContributions to Conferences: AbstractsAdverse Outcomes Post-initiation of Systemic Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease: A Long-term Observational UK-based Study
ATS 2022Contributions to Journals: AbstractsClinical Remission in Severe Asthma: A Pooled Post hoc Analysis of the Patient Journey with Benralizumab
Advances in Therapy, vol. 39, no. 5, pp. 2065–2084Contributions to Journals: ArticlesImpact of initiating biologics in patients with severe asthma and on long-term oral corticosteroids or rescue steroids (GLITTER)
ATS 2022, D102Contributions to Journals: AbstractsPersistent Reductions in OCS Use in Patients with Severe, OCS-Dependent Asthma Treated with Dupilumab: LIBERTY ASTHMA TRAVERSE Study
ATS 2022, A2365Contributions to Journals: AbstractsPredicting Pneumonia events in COPD patients using medical records
ATS 2022Contributions to Journals: AbstractsPrevalence of comorbidities in adults with severe asthma: results from the International Severe Asthma Registry (ISAR)
ATS 2022Contributions to Journals: AbstractsPrototype ORACLE Score Validation in NOVELTY: Predicted versus Observed Asthma Exacerbation Rates
ATS 2022, A486Contributions to Journals: AbstractsRelationships Between Symptoms and Lung Function in Asthma and/or Chronic Obstructive Pulmonary Disease in the NOVELTY study
ATS 2022, A4013Contributions to Journals: AbstractsGlobal Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma
The Journal of Allergy and Clinical Immunology: In Practice, vol. 10, no. 5Contributions to Journals: ArticlesVariation in demographic and clinical characteristics of Patients with COPD receiving care in U.S. primary care: data from the Advancing the Patient EXperience (APEX) in COPD registry
Pragmatic and Observational Research, vol. 2022, no. 13, pp. 17-31Contributions to Journals: ArticlesUse of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial. (BICS)
Trials, vol. 23, no. 1, 307Contributions to Journals: Articles